Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26523274 | 1.00 | MEN1 (0.39) | MEN1MAPK1KMT2ADPP8DPP9 | |
| SCHEMBL21618343 | 0.86 | MEN1 (0.39) | MEN1MAPK1KMT2ADPP8DPP9 | |
| SCHEMBL19188365 | 0.85 | MEN1 (0.38) | MEN1MAPK1KMT2ADPP8DPP9 | |
| SCHEMBL19920585 | 0.84 | MEN1 (0.40) | MEN1MAPK1KMT2ADPP8DPP9 | |
| SCHEMBL16118673 | 0.83 | MEN1 (0.46) | MEN1MAPK1KMT2ADPP8DPP9 | |
| SCHEMBL23539219 | 0.82 | MEN1 (0.41) | MEN1MAPK1KMT2ADPP8DPP9 | |
| SCHEMBL17586287 | 0.82 | MEN1 (0.44) | MEN1MAPK1KMT2ADPP8DPP9 | |
| SCHEMBL18038894 | 0.82 | KMT2A (0.41) | MEN1MAPK1KMT2ADPP8DPP9 | |
| SCHEMBL24462325 | 0.81 | MEN1 (0.38) | MEN1MAPK1KMT2ADPP8DPP9 | |
| SCHEMBL16118624 | 0.81 | MEN1 (0.40) | MEN1MAPK1KMT2ADPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388595-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-3810597-B1 | 1,2,4-TRIAZOLE DERIVATIVES AS TANKYRASE INHIBITORS | UNIV OSLO HF (NO) | 2025-11-26 | — | — | EP | disclosed |
| WO-2025106780-A1 | RXFP1 RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2025-05-22 | — | — | WO | disclosed |
| US-20250145594-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2025-05-08 | — | — | US | disclosed |
| US-20250122159-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2025-04-17 | — | — | US | disclosed |
| US-12091392-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2024-09-17 | — | — | US | disclosed |
| CN-118239937-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-118239938-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-111094233-B | Compounds, compositions, and methods | 戴纳立制药公司 | 2024-03-15 | — | — | CN | disclosed |
| US-11926614-B2 | 1,2,4-triazole derivatives as tankyrase inhibitors | OSLO UNIVERSITETSSYKEHUS HF (NO) | 2024-03-12 | — | — | US | disclosed |
| WO-2022258023-A1 | COMPOUND AS CDK KINASE INHIBITOR AND USE THEREOF | 郑州同源康医药有限公司 | 2022-12-15 | — | — | WO | disclosed |
| US-11414420-B2 | Pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2022-08-16 | — | — | US | disclosed |
| EP-3717472-B1 | PYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2022-07-27 | — | — | EP | disclosed |
| US-20220177438-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2022-06-09 | — | — | US | disclosed |
| US-20220177438-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2022-06-09 | — | — | US | disclosed |
| WO-2022094244-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2022-05-05 | — | — | WO | disclosed |
| US-11236100-B2 | Modulators of eukaryotic initiation factor 2B, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2022-02-01 | — | — | US | disclosed |
| WO-2022008896-A1 | TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS. | GOLDING, LOUISE (GB) | 2022-01-13 | — | — | WO | disclosed |
| US-20210147435-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2021-05-20 | — | — | US | disclosed |
| WO-2019243822-A1 | 1,2,4-TRIAZOLE DERIVATIVES AS TANKYRASE INHIBITORS | OSLO UNIVERSITETSSYKEHUS HF (NO) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177438-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | EIF4EBP1, EIF4B, EIF4E | MEN1 2342/4885MAPK1 2998/4885KMT2A 3876/4885 |
| US-11236100-B2 | Modulators of eukaryotic initiation factor 2B, compositions and methods | EIF4EBP1, EIF4B, EIF2B2 | MEN1 3106/4885MAPK1 2922/4885KMT2A 3643/4885 |
| US-12091392-B2 | Compounds, compositions and methods | EIF4EBP1, EIF4B, EIF4E | MEN1 2342/4885MAPK1 2998/4885KMT2A 3876/4885 |
| US-20250145594-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | MEN1 4684/4885MAPK1 339/4885KMT2A 4179/4885 |
| US-20250388595-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B, COMPOSITIONS AND METHODS | EIF2B1, EIF4EBP1, EIF2B3 | MEN1 3690/4885MAPK1 2878/4885KMT2A 4120/4885 |
| US-11926614-B2 | 1,2,4-triazole derivatives as tankyrase inhibitors | GBA3, CBR3, TECR | MEN1 3696/4885MAPK1 2168/4885KMT2A 4273/4885 |
| US-11414420-B2 | Pyrimidine derivatives | TYMS, DPYD, TYMP | MEN1 2275/4885MAPK1 3096/4885KMT2A 2112/4885 |
| US-20210147435-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | EIF4EBP1, EIF4B, EIF4E | MEN1 2284/4885MAPK1 3122/4885KMT2A 3980/4885 |
| US-20250122159-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | EIF4EBP1, EIF4B, EIF4E | MEN1 2342/4885MAPK1 2998/4885KMT2A 3876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.